期刊文献+

1例口服依托考昔致Stevens-Johnson综合征病例及文献分析 被引量:1

A case report of Stevens-Johnson syndrome caused by oral etoricoxib and lliterture review
原文传递
导出
摘要 依托考昔是一种高选择性COX-2抑制剂,因胃肠道不良反应少,广泛用于各类疼痛疾病的治疗,但其可能引起Stevens-Johnson综合征(Stevens-Johnson syndrome, SJS)和中毒性表皮坏死松懈症(toxic epidermal necrolysis, TEN),病死率高,且国内尚未见报道,本文报道一病例:患者,女,56岁,因诊断双膝骨关节炎给予依托考昔片60 mg qd治疗,服药24 h后出现全身多发红斑,伴瘙痒;口腔、外阴黏膜糜烂伴疼痛,伴发热、结膜充血、咳嗽、咳黄痰、喘累、呕吐、肝功能受损、三系减少等非特异性症状。通过积极给予糖皮质激素、人免疫球蛋白等治疗得到有效缓解。另外,还对国外的相关文献资料进行复习总结,以给临床医生、药师及护士在依托考昔致SJS的早期发现和治疗中提供警示和借鉴。
作者 向翼 王璇 戴艺 欧燕 谢明富 蒲俊勇 孟娅莉 余琳 XIANG Yi;WANG Xuan;DAI Yi;OU Yan;XIE Ming-fu;PU Jun-yong;MENG Ya-li;YU Lin(Department of Pharmacy,The People's Hospital of Qijiang District,Chongqing 401420,China;Department of Pharmacy,The Second Affiliated Hospital of Army Medical University,Chongqing 400037,China;Department of Medical Equipment,The People's Hospital of Qijiang District,Chongqing 401420,China)
出处 《中国医院药学杂志》 CAS 北大核心 2023年第2期232-236,共5页 Chinese Journal of Hospital Pharmacy
基金 重庆市綦江区科技计划项目(编号:2021176)。
  • 相关文献

参考文献2

二级参考文献22

  • 1SHAUNTA D M, KIMI S V, TONI L ,et al. Ripley etoricoxib: a highly selective COX-2 inhibitor[J]. Ann Pharmacother,2005,39 : 854 - 862.
  • 2RIENDEAU M D, PERCIVAL C, BRIDEA U,et al. Etoricoxib etoricoxib ( MK-0663 ) : preelinieal profile and comparison with other agents that selectively inhibit cyclooxygenase-2[ J]. J Pharmacol Exp Ther, 2001, 296: 558.
  • 3JULES I,SCHWART Z, PHAR M D,et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 Versus COX-I in healthy subjects [ J ]. J Clin Pharmacol , 2008,48:745-754.
  • 4LAINE L, CURTIS S P, LANGMAN M, et al. Lower gastrointestinal events in a double-blind trial of the cyclooxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac [ J ]. Gastroenterology, 2008, 135(5): 1517-1525.
  • 5BINGHAM C O, SEBBA A I, RUBIN B R, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies [ J ]. Rheumatology, 2007,46 : 496 - 507.
  • 6SCHWARTZ A L, DALLOB P J. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 Versus COX-1 in healthy subjects [ J ]. J Clin Pharmacol, 2008,48 : 745 - 754.
  • 7AGRAWAL N G, PORRAS A G, MATrHEWS C Z, et al. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers [ J ]. Clin Pharmacol, 2001,41 : 1106 - 1110.
  • 8DAVID R, RITA A, HALPIN L A,et al. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers[ J ]. Drug Metab Dispos, 2003, 31 : 224.
  • 9GOTYESDIENER K, SCHNITZER T, FISHER C, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis [ J ]. Rheumatology, 2002,41 : 1052 - 1061.
  • 10SCHUMACHER H R, JUDITH A B, DAVID I D, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis [ J ]. BMJ, 2002,324 : 1488 - 1492.

共引文献24

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部